| Year |
Citation |
Score |
| 2024 |
Wang X, DeFilippis RA, Yan W, Shah NP, Li HY. Overcoming Secondary Mutations of Type II Kinase Inhibitors. Journal of Medicinal Chemistry. PMID 38837951 DOI: 10.1021/acs.jmedchem.3c01629 |
0.326 |
|
| 2024 |
Leyte-Vidal A, Garrido Ruiz D, DeFilippis R, Leske IB, Rea D, Phan S, Miller KB, Hu F, Mase A, Shan Y, Hantschel O, Jacobson MP, Shah NP. BCR::ABL1 Kinase N-lobe Mutants Confer Moderate to High Degrees of Resistance to Asciminib. Blood. PMID 38643492 DOI: 10.1182/blood.2023022538 |
0.358 |
|
| 2024 |
Jabbour E, Apperley J, Cortes J, Rea D, Deininger M, Abruzzese E, Chuah C, DeAngelo DJ, Hochhaus A, Lipton JH, Mauro M, Nicolini F, Pinilla-Ibarz J, Rosti G, Rousselot P, ... Shah NP, et al. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. PMID 38287132 DOI: 10.1038/s41375-024-02159-0 |
0.337 |
|
| 2023 |
Winn AN, Atallah E, Cortes J, Deininger MWN, Kota V, Larson RA, Moore JO, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Shah NP, Thompson JE, Flynn KE. Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia. Jama Network Open. 6: e2347950. PMID 38109114 DOI: 10.1001/jamanetworkopen.2023.47950 |
0.338 |
|
| 2023 |
Wang X, DeFilippis RA, Weldemichael T, Gunaganti N, Tran P, Leung YK, Shah NP, Li HY. An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L. European Journal of Medicinal Chemistry. 264: 115977. PMID 38056299 DOI: 10.1016/j.ejmech.2023.115977 |
0.346 |
|
| 2023 |
Wang X, DeFilippis RA, Leung YK, Shah NP, Li HY. N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants. Bioorganic Chemistry. 143: 106966. PMID 37995643 DOI: 10.1016/j.bioorg.2023.106966 |
0.355 |
|
| 2022 |
Kantarjian HM, Jabbour E, Deininger M, Abruzzese E, Apperley J, Cortes J, Chuah C, DeAngelo DJ, DiPersio J, Hochhaus A, Lipton J, Nicolini FE, Pinilla-Ibarz J, Rea D, Rosti G, ... ... Shah NP, et al. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. American Journal of Hematology. PMID 36054756 DOI: 10.1002/ajh.26686 |
0.335 |
|
| 2021 |
Zhang L, Lakkaniga NR, Bharate JB, Mcconnell N, Wang X, Kharbanda A, Leung YK, Frett B, Shah NP, Li HY. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor. European Journal of Medicinal Chemistry. 225: 113776. PMID 34479037 DOI: 10.1016/j.ejmech.2021.113776 |
0.373 |
|
| 2021 |
Smith CC, Viny AD, Massi E, Kandoth C, Socci ND, Rapaport F, Najm M, Medina-Martinez JS, Papaemmanuil E, Tarver TC, Hsu HH, Le MH, West B, Bollag G, Taylor BS, ... ... Shah NP, et al. Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34103301 DOI: 10.1158/1078-0432.CCR-20-3458 |
0.348 |
|
| 2020 |
Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, et al. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. Jama Oncology. PMID 33180106 DOI: 10.1001/jamaoncol.2020.5774 |
0.355 |
|
| 2020 |
Mali RS, Zhang Q, DeFilippis R, Cavazos A, Kuruvilla VM, Raman J, Mody V, Choo EF, Dail M, Shah NP, Konopleva M, Sampath D, Lasater EA. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica. PMID 32414851 DOI: 10.3324/Haematol.2019.244020 |
0.43 |
|
| 2019 |
Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson S, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Pane F, Nicolini FE, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leukemia & Lymphoma. 1-10. PMID 31647335 DOI: 10.1080/10428194.2019.1675879 |
0.433 |
|
| 2019 |
Apsel Winger B, Cortopassi WA, Garrido Ruiz D, Ding L, Jang K, Leyte-Vidal A, Zhang N, Esteve-Puig R, Jacobson MP, Shah NP. ATP-competitive inhibitors midostaurin and avapritinib have distinct resistance profiles in exon 17-mutant KIT. Cancer Research. PMID 31270078 DOI: 10.1158/0008-5472.Can-18-3139 |
0.45 |
|
| 2019 |
Shah NP. NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 611-613. PMID 31117031 DOI: 10.6004/Jnccn.2019.5013 |
0.42 |
|
| 2019 |
McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJ, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, ... ... Shah NP, et al. Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discovery. PMID 31088841 DOI: 10.1158/2159-8290.Cd-18-1453 |
0.48 |
|
| 2019 |
Flynn KE, Weinfurt KP, Lin L, Radich JP, Schiffer CA, Mauro MJ, Pinilla Ibarz J, Moore JO, Larson RA, Oehler VG, Deininger MW, Thompson JE, Shah NP, Wadleigh M, Ritchie EK, et al. Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia Blood. 134: 705-705. DOI: 10.1182/Blood-2019-126002 |
0.377 |
|
| 2019 |
Yamatani K, Ai T, Saito K, Yang H, Suzuki K, Hori A, Murakami-Tonami Y, Zhang W, Carter BZ, Kinjo S, Ikeo K, Kazuhiro K, Harada H, Miida T, Shah NP, et al. Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations Blood. 134: 1264-1264. DOI: 10.1182/Blood-2019-124685 |
0.336 |
|
| 2019 |
Breccia M, Cortes JE, Shah NP, Saglio G, Jiménez-Velasco A, Coutre PL, Brun A, DeGutis I, Bathena S, Sy O, Jabbour E. Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial Blood. 134: 4155-4155. DOI: 10.1182/Blood-2019-121872 |
0.322 |
|
| 2019 |
Shah NP, García-Gutiérrez JV, Jiménez-Velasco A, Larson S, Saussele S, Rea D, Mahon F, Levy MY, Gómez-Casares MT, Luciano L, Nicolini F, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. DASFREE: Treatment-Free Remission (TFR) After Discontinuation of Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR) Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.07.253 |
0.362 |
|
| 2018 |
Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hobbs G, Jagasia M, Kantarjian HM, Maness L, Metheny L, ... ... Shah NP, et al. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 1108-1135. PMID 30181422 DOI: 10.6004/Jnccn.2018.0071 |
0.413 |
|
| 2018 |
Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica. PMID 30093398 DOI: 10.3324/Haematol.2018.188987 |
0.399 |
|
| 2018 |
Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, ... ... Shah NP, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. The Lancet. Oncology. PMID 29859851 DOI: 10.1016/S1470-2045(18)30240-7 |
0.454 |
|
| 2018 |
Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, et al. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. Bmc Cancer. 18: 359. PMID 29609532 DOI: 10.1186/S12885-018-4273-1 |
0.42 |
|
| 2018 |
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, ... ... Shah NP, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. PMID 29567798 DOI: 10.1182/Blood-2016-09-739086 |
0.412 |
|
| 2018 |
Bharate JB, McConnell N, Naresh G, Zhang L, Lakkaniga NR, Ding L, Shah NP, Frett B, Li HY. Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT. Scientific Reports. 8: 3722. PMID 29487300 DOI: 10.1038/S41598-018-21839-3 |
0.396 |
|
| 2018 |
Shah NP. Front-Line Treatment Options for Chronic-Phase Chronic Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 36: 220-224. PMID 29206554 DOI: 10.1200/Jco.2017.75.4663 |
0.336 |
|
| 2018 |
Jang K, Shah NP. Multiparameter Single Cell Analysis to Identify Immune Cell States That May Contribute to Successful Treatment Discontinuation in Patients with Chronic Myeloid Leukemia Blood. 132: 2999-2999. DOI: 10.1182/Blood-2018-99-119267 |
0.338 |
|
| 2018 |
Shah NP, Gutiérrez JVG, Jiménez-Velasco A, Larson S, Saussele S, Rea D, Mahon F, Levy MY, Gómez-Casares MT, Pane F, Nicolini F, Mauro MJ, Sy O, Regueira PM, Lipton JH. Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR) Blood. 132: 4253-4253. DOI: 10.1182/Blood-2018-99-116563 |
0.37 |
|
| 2018 |
George G, Atallah EL, Mauro MJ, Goldberg SL, Baim A, Guhl J, Hinman A, Cortes JE, Deininger MW, Druker BJ, Kota VK, Larson RA, Lipton JH, Moore JO, Oehler VG, ... ... Shah NP, et al. Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey Blood. 132: 5843-5843. DOI: 10.1182/Blood-2018-99-114589 |
0.326 |
|
| 2018 |
Yamatani K, Tabe Y, Saito K, Yang H, Murakami-Tonami Y, Suzuki K, Zhang W, Kinjo S, Ikeo K, Mogushi K, Hosoya M, Yamaguchi S, Harada H, Miida T, Shah NP, et al. Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3-ITD AML with Secondary Acquired Mutations Blood. 132: 3944-3944. DOI: 10.1182/Blood-2018-99-109957 |
0.393 |
|
| 2018 |
Shah NP, García-Gutiérrez JV, Jiménez-Velasco A, Larson S, Saussele S, Rea D, Mahon F, Levy MY, Gómez-Casares MT, Pane F, Nicolini F, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. Treatment-Free Remission (TFR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DMR) Discontinuing Dasatinib (DASFREE) Clinical Lymphoma, Myeloma & Leukemia. 18. DOI: 10.1016/J.Clml.2018.07.090 |
0.362 |
|
| 2017 |
Metts J, Bradley HL, Wang Z, Shah NP, Kapur R, Arbiser JL, Bunting KD. Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells. Scientific Reports. 7: 4447. PMID 28667329 DOI: 10.1038/S41598-017-04796-1 |
0.449 |
|
| 2017 |
Saglio G, le Coutre P, Cortes J, Mayer J, Rowlings P, Mahon FX, Kroog G, Gooden K, Subar M, Shah NP. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. Annals of Hematology. PMID 28534184 DOI: 10.1007/S00277-017-3012-Z |
0.351 |
|
| 2017 |
Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, Chin CS, Asthana S, Olshen A, Travers KJ, Wang S, Levis MJ, Perl AE, Radich JP, Shah NP. Heterogeneous resistance to quizartinib in acute myeloid leukemia (AML) revealed by single cell analysis. Blood. PMID 28490572 DOI: 10.1182/Blood-2016-04-711820 |
0.461 |
|
| 2017 |
Mueller M, Baccarani M, Deininger MW, Guilhot F, Hochhaus A, Hughes TP, Shah NP, Talpaz M, Lustgarten S, Santillana S, Rivera VM, Clackson TP, Cortes JE. Impact of early landmark responses with ponatinib on 4-yr outcomes in CP-CML patients (pts) in PACE, a pivotal phase II trial. Journal of Clinical Oncology. 35: 7050-7050. DOI: 10.1200/Jco.2017.35.15_Suppl.7050 |
0.35 |
|
| 2017 |
Kantarjian HM, Pinilla-Ibarz J, Le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, Baccarani M, Lustgarten S, Santillana S, Guilhot F, Deininger MW, Hochhaus A, ... ... Shah NP, et al. Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts). Journal of Clinical Oncology. 35: 7012-7012. DOI: 10.1200/Jco.2017.35.15_Suppl.7012 |
0.373 |
|
| 2017 |
Shah NP, Gutiérrez JVG, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, Mahon F, Levy M, Gómez-Casares MT, Pane F, Nicolini F, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE) Blood. 130: 314-314. DOI: 10.1182/Blood.V130.Suppl_1.314.314 |
0.346 |
|
| 2017 |
McMahon CM, Canaani J, Rea B, Sargent RL, Morrissette JJD, Lieberman DB, Watt C, Schwartz GW, Faryabi RB, Ferng TT, Shah NP, Smith CC, Carroll M, Perl AE. Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia Blood. 130: 295-295. DOI: 10.1182/Blood.V130.Suppl_1.295.295 |
0.448 |
|
| 2017 |
Cortes JE, Nicolini FE, Hochhaus A, Coutre PDl, Kim D, Pinilla-Ibarz J, Paquette R, Chuah C, Apperley JF, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Mueller MC, Gambacorti-Passerini C, ... ... Shah NP, et al. Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Blood. 130: 2896-2896. DOI: 10.1182/Blood.V130.Suppl_1.2896.2896 |
0.314 |
|
| 2017 |
Hochhaus A, Cortes JE, Kim D, Pinilla-Ibarz J, Coutre PDl, Paquette R, Chuah C, Nicolini FE, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Mueller MC, Gambacorti-Passerini C, Castagnetti F, ... ... Shah NP, et al. Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study Blood. 130: 1617-1617. DOI: 10.1182/Blood.V130.Suppl_1.1617.1617 |
0.351 |
|
| 2017 |
Mauro MJ, Cortes JE, Hochhaus A, Shah NP, Atallah E, Abaskharoun M, Sy O, Saglio G. Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISION Clinical Lymphoma Myeloma and Leukemia. 17: S14-S15. DOI: 10.1016/J.Clml.2017.09.042 |
0.341 |
|
| 2017 |
Mauro MJ, Cortes JE, Hochhaus A, Shah NP, Atallah EL, Abaskharoun M, Sy O, Saglio G. Five-Year Efficacy and Safety of Dasatinib and Imatinib by Baseline Comorbidity and Age in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) from DASISION Clinical Lymphoma Myeloma and Leukemia. 17: S312-S313. DOI: 10.1016/J.Clml.2017.07.113 |
0.341 |
|
| 2017 |
Cortes JE, Kantarjian HM, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Talpaz M, Baccarani M, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Lustgarten S, Santillana S, et al. 5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia Clinical Lymphoma Myeloma and Leukemia. 17: S307-S308. DOI: 10.1016/J.Clml.2017.07.105 |
0.335 |
|
| 2016 |
Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO, ... ... Shah NP, et al. NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 1505-1512. PMID 27956535 DOI: 10.6004/Jnccn.2016.0162 |
0.311 |
|
| 2016 |
Lee BJ, Shah NP. Identification and characterization of activating ABL1 1b kinase mutations: Impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors. Leukemia. PMID 27890928 DOI: 10.1038/Leu.2016.353 |
0.473 |
|
| 2016 |
Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27217448 DOI: 10.1200/Jco.2015.64.8899 |
0.382 |
|
| 2016 |
Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. American Journal of Hematology. PMID 27192969 DOI: 10.1002/Ajh.24423 |
0.433 |
|
| 2016 |
Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, ... Shah NP, et al. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. Jci Insight. 1: e85630. PMID 27158668 DOI: 10.1172/Jci.Insight.85630 |
0.503 |
|
| 2016 |
Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, ... ... Shah NP, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. The Lancet. Oncology. PMID 27083332 DOI: 10.1016/S1470-2045(16)00080-2 |
0.409 |
|
| 2016 |
Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K, Mustjoki S, Mohamed H, Shah NP. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer. PMID 26998677 DOI: 10.1002/Cncr.29933 |
0.43 |
|
| 2016 |
Shah NP, Saglio G, Hochhaus A, Bilmes R, Li L, Cortes JE. Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION. Journal of Clinical Oncology. 34: 7055-7055. DOI: 10.1200/Jco.2016.34.15_Suppl.7055 |
0.379 |
|
| 2016 |
Müller MC, Baccarani M, Deininger MW, Guilhot F, Hochhaus A, Hughes TP, Shah NP, Talpaz M, Lustgarten S, Rivera VM, Clackson TP, Haluska FG, Cortes JE. Impact of landmark responses on 3-year (yr) outcomes with ponatinib in heavily pretreated CP-CML patients (pts). Journal of Clinical Oncology. 34: 7053-7053. DOI: 10.1200/Jco.2016.34.15_Suppl.7053 |
0.351 |
|
| 2016 |
Cortes JE, Pinilla-Ibarz J, Le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, Baccarani M, Lustgarten S, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, ... ... Shah NP, et al. 4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia. Journal of Clinical Oncology. 34: 7013-7013. DOI: 10.1200/Jco.2016.34.15_Suppl.7013 |
0.415 |
|
| 2016 |
Zeng Z, Ly C, Mak D, Shah NP, Konopleva M, Andreeff M. AMG925, a Dual FLT3-CDK4/6 Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML Progenitor/Stem Cells Blood. 128: 3938-3938. DOI: 10.1182/Blood.V128.22.3938.3938 |
0.48 |
|
| 2016 |
Jabbour EJ, Cortes JE, Talpaz M, Baccarani M, Mauro MJ, Hochhaus A, Hughes TP, Guilhot F, Deininger MW, Shah N, Bixby DL, Flinn IW, O'Hare T, Lustgarten S, Rivera VM, et al. Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation Blood. 128: 3067-3067. DOI: 10.1182/Blood.V128.22.3067.3067 |
0.369 |
|
| 2016 |
Mauro MJ, Cortes JE, Kantarjian HM, Shah NP, Bixby DL, Flinn IW, O'Hare T, Rivera VM, Lustgarten S, Santillana S, Heinrich MC, Druker BJ, Deininger MW, Talpaz M. Ponatinib in Chronic-Phase Chronic Myeloid Leukemia Patients: Final Report from a Phase 1 Trial Blood. 128: 3063-3063. DOI: 10.1182/Blood.V128.22.3063.3063 |
0.387 |
|
| 2016 |
Ly C, Zhang W, Ruvolo V, Shah NP, Andreeff M. Mechanism-Based Combinatorial Strategy for Overcoming FLT3-Inhibitor Resistance in Dual FLT3 ITD and TKD Point Mutations Blood. 128: 2328-2328. DOI: 10.1182/Blood.V128.22.2328.2328 |
0.466 |
|
| 2016 |
Shah NP, Paquette R, Müller MC, Saussele S, Garcìa-Gutiérrez V, Jiménez-Velasco A, Nicolini F, Mauro MJ, Mahon F, Rea D, Martin-Regueira P, Subar M, Li L, Lipton JH. Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study Blood. 128: 1895-1895. DOI: 10.1182/Blood.V128.22.1895.1895 |
0.411 |
|
| 2016 |
Tabe Y, Sekihara K, Saitoh K, Monma N, Ikeo K, Kaczkowski B, Zhang W, Yamanaka Y, Miida T, Shah NP, Harada H, Hayashizaki Y, Konopleva M, Andreeff M. Cap Analysis of Gene Expression (CAGE) Sequencing Reveals Alterations of the Transcriptional Signatures of FLT3-ITD with Secondary D835 TKD Mutations in Acute Myeloid Leukemia Blood. 128: 1530-1530. DOI: 10.1182/Blood.V128.22.1530.1530 |
0.457 |
|
| 2016 |
Talpaz M, Müller M, Baccarani M, Deininger M, Guilhot F, Hochhaus A, Hughes T, Shah N, Lustgarten S, Rivera V, Clackson T, Haluska F, Cortes J. Impact of Landmark Responses on 3-Year Outcomes in CP-CML Patients in the Ponatinib PACE Trial Clinical Lymphoma Myeloma and Leukemia. 16: S61-S62. DOI: 10.1016/J.Clml.2016.07.089 |
0.306 |
|
| 2016 |
Cortes J, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini F, Apperley J, Khoury HJ, Talpaz M, Baccarani M, Lustgarten S, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, ... ... Shah NP, et al. 4-Year Results from the Pivotal Phase 2 PACE Trial: Efficacy and Safety in Heavily Pretreated Leukemia Patients Clinical Lymphoma Myeloma and Leukemia. 16: S56. DOI: 10.1016/J.Clml.2016.07.082 |
0.321 |
|
| 2015 |
le Coutre PD, Hughes TP, Mahon FX, Kim DW, Steegmann JL, Shah NP, Gooden K, Wallis N, Cortes JE. Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. Leukemia. PMID 26686247 DOI: 10.1038/Leu.2015.352 |
0.442 |
|
| 2015 |
Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Müller MC, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, et al. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. PMID 26603839 DOI: 10.1182/Blood-2015-08-660977 |
0.45 |
|
| 2015 |
Lasater EA, Massi ES, Stecula A, Politi J, Tan SK, Smith CC, Gunthorpe M, Holmes JP, Chehab F, Sali A, Shah NP. Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib. Leukemia. PMID 26511402 DOI: 10.1038/Leu.2015.303 |
0.387 |
|
| 2015 |
Apsel Winger B, Shah NP. PPARγ: Welcoming the New Kid on the CML Stem Cell Block. Cancer Cell. 28: 409-11. PMID 26461088 DOI: 10.1016/J.Ccell.2015.09.017 |
0.352 |
|
| 2015 |
Kesarwani M, Huber E, Kincaid Z, Evelyn CR, Biesiada J, Rance M, Thapa MB, Shah NP, Meller J, Zheng Y, Azam M. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Scientific Reports. 5: 14538. PMID 26419724 DOI: 10.1038/Srep14538 |
0.38 |
|
| 2015 |
Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, Mattei D, Guha M, Rea D, Peacock A. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. American Journal of Hematology. 90: 1060-4. PMID 26284693 DOI: 10.1002/Ajh.24174 |
0.363 |
|
| 2015 |
Smith CC, Lin K, Stecula A, Sali A, Shah NP. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia. PMID 26108694 DOI: 10.1038/Leu.2015.165 |
0.435 |
|
| 2015 |
Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, et al. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 424-34. PMID 25870379 DOI: 10.6004/Jnccn.2015.0058 |
0.335 |
|
| 2015 |
Smith CC, Zhang C, Lin KC, Lasater EA, Zhang Y, Massi E, Damon LE, Pendleton M, Bashir A, Sebra R, Perl A, Kasarskis A, Shellooe R, Tsang G, Carias H, ... ... Shah NP, et al. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Cancer Discovery. 5: 668-79. PMID 25847190 DOI: 10.1158/2159-8290.Cd-15-0060 |
0.44 |
|
| 2015 |
Shah N, Andrews J, Goodnough LT. Transfusions for anemia in adult and pediatric patients with malignancies. Blood Reviews. PMID 25796130 DOI: 10.1016/J.Blre.2015.02.001 |
0.305 |
|
| 2015 |
Frett B, McConnell N, Smith CC, Wang Y, Shah NP, Li HY. Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. European Journal of Medicinal Chemistry. 94: 123-31. PMID 25765758 DOI: 10.1016/J.Ejmech.2015.02.052 |
0.408 |
|
| 2015 |
Cortes JE, Kim DG, Pinilla-Ibarz J, Le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, Baccarani M, Lustgarten S, Haluska FG, Guilhot F, ... ... Shah NP, et al. Efficacy and safety of ponatinib in heavily pretreated leukemia patients in the PACE trial: 3-year results. Journal of Clinical Oncology. 33: e18052-e18052. DOI: 10.1200/Jco.2015.33.15_Suppl.E18052 |
0.445 |
|
| 2015 |
Khoury HJ, Baccarani M, Guilhot F, Hochhaus A, Hughes TP, Lipton JH, Lustgarten S, Yanase K, Conlan MG, Cortes JE, Deininger MW, Kantarjian HM, Shah NP, Talpaz M, Mauro MJ. Elevated blood pressure (BP) and adverse events (AEs) of hypertension (HTN) in ponatinib (PON) leukemia trials. Journal of Clinical Oncology. 33: 7049-7049. DOI: 10.1200/Jco.2015.33.15_Suppl.7049 |
0.38 |
|
| 2015 |
Talpaz M, Cortes JE, Kantarjian HM, Shah NP, Bixby DL, Flinn I, O'Hare TJ, Hu S, Rivera VM, Clackson TP, Conlan MG, Haluska FG, Druker BJ, Deininger MW, Mauro MJ. Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON). Journal of Clinical Oncology. 33: 7047-7047. DOI: 10.1200/Jco.2015.33.15_Suppl.7047 |
0.427 |
|
| 2015 |
Smith CC, Viny AD, Massi ES, Kandoth C, Socci ND, Hsu H, West B, Bollag G, Taylor BS, Levine RL, Shah NP. Recurrent Mutations in CCND3 Confer Clinical Resistance to FLT3 Inhibitors Blood. 126: 677-677. DOI: 10.1182/Blood.V126.23.677.677 |
0.476 |
|
| 2015 |
Hochhaus A, Cortes JE, Kim D, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, ... ... Shah NP, et al. Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial Blood. 126: 4025-4025. DOI: 10.1182/Blood.V126.23.4025.4025 |
0.397 |
|
| 2015 |
Metts JL, Bradley HL, Shah NP, Kapur R, Arbiser JL, Bunting KD. Imipramine Blue Sensitively and Selectively Targets FLT3 and c-Kit Mutant Acute Myeloid Leukemia Blood. 126: 3688-3688. DOI: 10.1182/Blood.V126.23.3688.3688 |
0.478 |
|
| 2015 |
Lee BJ, Shah NP. Identification of TKI-Sensitive Point Mutations That Activate c-ABL Kinase Activity and Transformation Potential and Confer in Vitro Resistance to the Allosteric ABL Inhibitor GNF-5 Blood. 126: 17-17. DOI: 10.1182/Blood.V126.23.17.17 |
0.461 |
|
| 2015 |
Tran TH, Nguyen JV, Smith CC, Roberts KG, Mullighan CG, Shah NP, Loh ML. Identifying Drug-Resistant Mutations in Ebf1-Pdgfrb Ph-like Acute Lymphoblastic Leukemia Blood. 126: 1423-1423. DOI: 10.1182/Blood.V126.23.1423.1423 |
0.473 |
|
| 2015 |
Shah NP. Abstract IA16: Acquired resistance to targeted therapeutics in hematologic malignancies Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Ia16 |
0.37 |
|
| 2015 |
Smith CC, Paguirigan A, Chin C, Brown M, Parker W, Levis MJ, Perl AE, Travers K, Kasap C, Radich JP, Branford S, Shah NP. Abstract NG02: Polyclonal and heterogeneous resistance to targeted therapy in leukemia Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ng02 |
0.459 |
|
| 2015 |
Graham D, DeRyckere D, Minson K, Smith C, Hill A, Huey M, Lasater E, Wang X, Shah N, Frye S, Shelton Earp H. Development of novel small molecule MerTK and Flt3 tyrosine kinase inhibitors for treatment of acute leukemia Annals of Oncology. 26: ii6. DOI: 10.1093/Annonc/Mdv082.2 |
0.477 |
|
| 2015 |
Pritchard JR, Lustgarten S, Hodgson G, Baccarani M, Cortes JE, Deininger MW, Guilhot F, Hochhaus A, Hughes TP, Shah NP, Talpaz M, Clackson T, Haluska FG, Knickerbocker R, Rivera VM. High-Resolution Analysis of the Relationship Between Ponatinib Dose and Molecular Response in CP-CML Patients in the PACE Trial Clinical Lymphoma Myeloma and Leukemia. 15: S212. DOI: 10.1016/J.Clml.2015.04.077 |
0.304 |
|
| 2015 |
Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes TP, Kantarjian H, ... Shah NP, et al. EPIC: A Phase 3 Trial of Ponatinib Compared With Imatinib in CP-CML Patients Clinical Lymphoma Myeloma and Leukemia. 15: S211. DOI: 10.1016/J.Clml.2015.04.076 |
0.382 |
|
| 2014 |
Radich JP, Shah NP, Mauro MJ. Integrating current treatment options for TKI-resistant chronic myeloid leukemia Clinical Advances in Hematology &Amp; Oncology : H&Amp;O. 12. PMID 25768408 |
0.357 |
|
| 2014 |
Warkentin AA, Lopez MS, Lasater EA, Lin K, He BL, Leung AY, Smith CC, Shah NP, Shokat KM. Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. Elife. 3. PMID 25531068 DOI: 10.7554/Elife.03445 |
0.481 |
|
| 2014 |
Chatterjee A, Ghosh J, Ramdas B, Mali RS, Martin H, Kobayashi M, Vemula S, Canela VH, Waskow ER, Visconte V, Tiu RV, Smith CC, Shah N, Bunting KD, Boswell HS, et al. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. Cell Reports. 9: 1333-48. PMID 25456130 DOI: 10.1016/J.Celrep.2014.10.039 |
0.404 |
|
| 2014 |
O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, Curtin P, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, ... ... Shah NP, et al. Chronic myelogenous leukemia, version 1.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 1590-610. PMID 25361806 DOI: 10.6004/Jnccn.2014.0159 |
0.394 |
|
| 2014 |
Lasater EA, Lin KC, Wang Q, Quino McCreery M, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP. Crenolanib is a selective type i pan-FLT3 inhibitor Catherine Choy Smith1,2 Proceedings of the National Academy of Sciences of the United States of America. 111: 5319-5324. PMID 24623852 DOI: 10.1073/Pnas.1320661111 |
0.497 |
|
| 2014 |
Ciceri P, Müller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C, Martin S, Wodicka LM, Shah NP, Treiber DK, Knapp S. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nature Chemical Biology. 10: 305-12. PMID 24584101 DOI: 10.1038/Nchembio.1471 |
0.421 |
|
| 2014 |
Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 123: 2317-24. PMID 24569263 DOI: 10.1182/Blood-2013-10-532341 |
0.363 |
|
| 2014 |
Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leukemia Research. 38: 316-22. PMID 24374145 DOI: 10.1016/J.Leukres.2013.12.006 |
0.371 |
|
| 2014 |
Asmussen J, Lasater EA, Tajon C, Oses-Prieto J, Jun YW, Taylor BS, Burlingame A, Craik CS, Shah NP. MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction. Cancer Discovery. 4: 200-15. PMID 24362263 DOI: 10.1158/2159-8290.Cd-13-0235 |
0.432 |
|
| 2014 |
Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 123: 494-500. PMID 24311723 DOI: 10.1182/Blood-2013-06-511592 |
0.429 |
|
| 2014 |
Politi J, Shah NP. What does a deep molecular response signify? Journal of Clinical Oncology. 32: 471-474. PMID 24297955 DOI: 10.1200/Jco.2013.52.8307 |
0.525 |
|
| 2014 |
Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, Müller MC, Radich JP, Shah NP. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leukemia Research. 38: 10-20. PMID 24131888 DOI: 10.1016/J.Leukres.2013.09.011 |
0.487 |
|
| 2014 |
Warkentin AA, Lopez MS, Lasater EA, Lin K, He B, Leung AY, Smith CC, Shah NP, Shokat KM. Author response: Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy Elife. DOI: 10.7554/Elife.03445.010 |
0.311 |
|
| 2014 |
Levis MJ, Martinelli G, Perl AE, Dombret H, Steffen B, Rousselot PH, Estey E, Shah NP, Gammon G, Trone D, Cortes JE. The Benefit of Treatment with Quizartinib and Subsequent Bridging to HSCT for FLT3-ITD(+) Patients with AML Journal of Clinical Oncology. 32: 7093-7093. DOI: 10.1200/Jco.2014.32.15_Suppl.7093 |
0.385 |
|
| 2014 |
Shah NP, Buettner A, Lankford M, Willey J, Neely DB, Green MR. Trends in first-line TKI prescribing preferences (PPrefs) among U.S.-based hematology-oncology physicians (HOPs) for patients with chronic phase chronic myelogenous leukemia (CP-CML). Journal of Clinical Oncology. 32: 7085-7085. DOI: 10.1200/Jco.2014.32.15_Suppl.7085 |
0.337 |
|
| 2014 |
Hochhaus A, Pinilla-Ibarz J, Kim D, Le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Baccarani M, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, ... ... Shah NP, et al. Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias. Journal of Clinical Oncology. 32: 7084-7084. DOI: 10.1200/Jco.2014.32.15_Suppl.7084 |
0.334 |
|
| 2014 |
Kantarjian HM, Kim D, Pinilla-Ibarz J, Le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, Baccarani M, Lustgarten S, Haluska FG, Guilhot F, ... ... Shah NP, et al. Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial. Journal of Clinical Oncology. 32: 7081-7081. DOI: 10.1200/Jco.2014.32.15_Suppl.7081 |
0.439 |
|
| 2014 |
Talpaz M, Cortes JE, Kantarjian HM, Shah NP, Bixby DL, Flinn I, O'Hare T, Hu S, Rivera VM, Clackson T, Turner CD, Haluska FG, Drucker BJ, Deininger MWN, Mauro MJ. Longer-term follow up of a phase 1 study of ponatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias. Journal of Clinical Oncology. 32: 7078-7078. DOI: 10.1200/Jco.2014.32.15_Suppl.7078 |
0.408 |
|
| 2014 |
Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Lustgarten S, Trede NS, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes TP, ... ... Shah NP, et al. EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML. Journal of Clinical Oncology. 32: 7023-7023. DOI: 10.1200/Jco.2014.32.15_Suppl.7023 |
0.354 |
|
| 2014 |
Shah NP, Rousselot P, Schiffer CA, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G. Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results Blood. 124: 520-520. DOI: 10.1182/Blood.V124.21.520.520 |
0.369 |
|
| 2014 |
Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, Coutre PL, Clark R, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, ... ... Shah NP, et al. Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Blood. 124: 519-519. DOI: 10.1182/Blood.V124.21.519.519 |
0.408 |
|
| 2014 |
Mueller MC, Baccarani M, Deininger MW, Guilhot F, Hochhaus A, Hughes TP, Shah NP, Talpaz M, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Cortes JE. Achieving Early Landmark Response Is Predictive of Outcomes in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib Blood. 124: 518-518. DOI: 10.1182/Blood.V124.21.518.518 |
0.391 |
|
| 2014 |
Talpaz M, Cortes JE, Kantarjian H, Shah NP, Bixby D, Flinn I, O'Hare T, Hu S, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Mauro MJ. Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Blood. 124: 4558-4558. DOI: 10.1182/Blood.V124.21.4558.4558 |
0.426 |
|
| 2014 |
Mauro MJ, Cortes JE, Hochhaus A, Baccarani M, Hughes TP, Guilhot F, Deininger MW, Kantarjian HM, Shah NP, Bixby D, Flinn I, Lustgarten S, Rivera VM, Haluska FG, Clackson T, et al. Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials Blood. 124: 4552-4552. DOI: 10.1182/Blood.V124.21.4552.4552 |
0.389 |
|
| 2014 |
Shah NP, Cortes JE, Martinelli G, Smith BD, Clarke E, Copland M, Strauss L, Talpaz M. Dasatinib Plus Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) with Resistance or Suboptimal Response to a Prior Tyrosine Kinase Inhibitor (TKI): Phase I Study CA180323 Blood. 124: 4539-4539. DOI: 10.1182/Blood.V124.21.4539.4539 |
0.432 |
|
| 2014 |
Saglio G, le Coutre P, Cortes JE, Mayer J, Rowlings PA, Mahon F, Kroog GS, Gooden K, Subar M, Preston JA, Shah NP. The Observed and Expected Incidence of Cardiovascular (CV) Ischemic Events in Dasatinib (DAS)-Treated Patients (pts) Across a Clinical Trial Program Blood. 124: 4534-4534. DOI: 10.1182/Blood.V124.21.4534.4534 |
0.334 |
|
| 2014 |
Minson KA, Smith CC, Lee-Sherick AB, DeRyckere D, Lasater E, Hill AA, Wang X, Frye SV, Earp HS, Shah NP, Graham DK. MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia Blood. 124: 3757-3757. DOI: 10.1182/Blood.V124.21.3757.3757 |
0.505 |
|
| 2014 |
Pritchard JR, Lustgarten S, Hodgson G, Baccarani M, Cortes JE, Deininger MW, Guilhot F, Hochhaus A, Hughes TP, Shah NP, Talpaz M, Clackson T, Haluska FG, Knickerbocker R, Rivera VM. High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib Blood. 124: 3153-3153. DOI: 10.1182/Blood.V124.21.3153.3153 |
0.36 |
|
| 2014 |
Cortes JE, Kim D, Pinilla-Ibarz J, Le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, ... ... Shah NP, et al. Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial Blood. 124: 3135-3135. DOI: 10.1182/Blood.V124.21.3135.3135 |
0.396 |
|
| 2014 |
Cortes JE, Saglio G, Baccarani M, Kantarjian HM, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Narayanan G, Bradley-Garelik B, Manos G, Hochhaus A. Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056) Blood. 124: 152-152. DOI: 10.1182/Blood.V124.21.152.152 |
0.362 |
|
| 2014 |
Quinn ER, Ciceri P, Müller-Knapp S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C, Wodicka LM, Shah NP, Knapp S, Treiber DK. Abstract 5387: Dual kinase/bromodomain inhibitors for rationally designed polypharmacology Cancer Research. 74: 5387-5387. DOI: 10.1158/1538-7445.Am2014-5387 |
0.431 |
|
| 2014 |
Ciceri P, Müller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C, Martin S, Wodicka LM, Shah NP, Treiber DK, Knapp S. Corrigendum: Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nature Chemical Biology. 10: 692-692. DOI: 10.1038/Nchembio0814-692D |
0.306 |
|
| 2014 |
Mauro MJ, Cortes JE, Kantarjian HM, Shah NP, Bixby D, Flinn IW, O’Hare T, Hu S, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. Safety and Durability of Ponatinib in Patients With Philadelphia Chromosome–Positive (Ph+) Leukemia: Long-term Follow-up of an Ongoing Phase 1 Study Clinical Lymphoma Myeloma and Leukemia. 14: S137-S138. DOI: 10.1016/J.Clml.2014.06.069 |
0.303 |
|
| 2014 |
Deininger MW, Cortes JE, Kim D, Nicolini FE, Talpaz M, Baccarani M, Müller MC, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Hochhaus A, Goldman JM, ... Shah NP, et al. Impact of Baseline Mutations on Response to Ponatinib and End of Treatment Mutation Analysis in Patients With Chronic Myeloid Leukemia Clinical Lymphoma Myeloma and Leukemia. 14: S136. DOI: 10.1016/J.Clml.2014.06.067 |
0.387 |
|
| 2013 |
O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, ... ... Shah NP, et al. Chronic Myelogenous Leukemia, Version 1.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 1327-40. PMID 24225967 DOI: 10.6004/Jnccn.2013.0157 |
0.391 |
|
| 2013 |
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, ... ... Shah NP, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. The New England Journal of Medicine. 369: 1783-96. PMID 24180494 DOI: 10.1056/Nejmoa1306494 |
0.482 |
|
| 2013 |
Shah N, Rutherford C, Matevosyan K, Shen YM, Sarode R. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). British Journal of Haematology. 163: 514-9. PMID 24111495 DOI: 10.1111/Bjh.12569 |
0.337 |
|
| 2013 |
Treiber DK, Shah NP. Ins and outs of kinase DFG motifs Chemistry and Biology. 20: 745-746. PMID 23790484 DOI: 10.1016/J.Chembiol.2013.06.001 |
0.357 |
|
| 2013 |
Smith CC, Shah NP. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 313-8. PMID 23714533 DOI: 10.1200/EdBook_AM.2013.33.313 |
0.378 |
|
| 2013 |
Shah NP, Talpaz M, Deininger MW, Mauro MJ, Flinn IW, Bixby D, Lustgarten S, Gozgit JM, Clackson T, Turner CD, Haluska FG, Kantarjian H, Cortes JE. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. British Journal of Haematology. 162: 548-52. PMID 23691988 DOI: 10.1111/Bjh.12382 |
0.488 |
|
| 2013 |
Abboud C, Berman E, Cohen A, Cortes J, DeAngelo D, Deininger M, Devine S, Druker B, Fathi A, Jabbour E, Jagasia M, Kantarjian H, Khoury J, Laneuville P, Larson R, ... ... Shah N, et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts Blood. 121: 4439-4442. PMID 23620577 DOI: 10.1182/Blood-2013-03-490003 |
0.308 |
|
| 2013 |
Sonnichsen D, Dorer DJ, Cortes J, Talpaz M, Deininger MW, Shah NP, Kantarjian HM, Bixby D, Mauro MJ, Flinn IW, Litwin J, Turner CD, Haluska FG. Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemotherapy and Pharmacology. 71: 1599-607. PMID 23609479 DOI: 10.1007/s00280-013-2160-7 |
0.357 |
|
| 2013 |
Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 121: 3165-71. PMID 23430109 DOI: 10.1182/Blood-2012-07-442871 |
0.477 |
|
| 2013 |
Lipton JH, Deininger MWN, Lustgarten S, Turner CD, Rivera VM, Clackson T, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes TP, Kantarjian HM, Shah NP, Talpaz M, Haluska FG. EPIC: A phase III randomized, open-label study of ponatinib versus imatinib in adult patients with newly diagnosed chronic myeloid leukemia in chronic phase. Journal of Clinical Oncology. 31: TPS7129-TPS7129. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps7129 |
0.466 |
|
| 2013 |
Mauro MJ, Cortes JE, Kantarjian HM, Shah NP, Bixby D, Flinn I, O'Hare T, Hu S, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MWN, Talpaz M. Safety and durability of ponatinib in patients with Philadelphia chromosome-positive (Ph+) leukemia: Long-term follow-up of an ongoing phase I study. Journal of Clinical Oncology. 31: 7063-7063. DOI: 10.1200/Jco.2013.31.15_Suppl.7063 |
0.45 |
|
| 2013 |
Perl AE, Dohner H, Rousselot PH, Marie J, Martinelli G, Shah NP, Levis MJ, Gammon G, Trone D, Cortes JE. Efficacy and safety of quizartinib (AC220) in patients age ≥ 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML). Journal of Clinical Oncology. 31: 7023-7023. DOI: 10.1200/Jco.2013.31.15_Suppl.7023 |
0.409 |
|
| 2013 |
Martinelli G, Perl AE, Dombret H, Kayser S, Steffen B, Rousselot PH, Estey E, Burnett AK, Shah NP, Gammon G, Trone D, Levis MJ, Cortes JE. Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia. Journal of Clinical Oncology. 31: 7021-7021. DOI: 10.1200/Jco.2013.31.15_Suppl.7021 |
0.422 |
|
| 2013 |
Cortes JE, Perl AE, Dombret H, Dohner H, Steffen B, Rousselot PH, Martinelli G, Estey E, Shah NP, Burnett AK, Gammon G, Trone D, Levis MJ. Response rate and bridging to hematopoietic stem cell transplantation (HSCT) with quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory AML after second-line chemotherapy or previous bone marrow transplant. Journal of Clinical Oncology. 31: 7012-7012. DOI: 10.1200/Jco.2013.31.15_Suppl.7012 |
0.402 |
|
| 2013 |
Deininger MWN, Cortes JE, Kim D, Nicolini FE, Talpaz M, Baccarani M, Müller MC, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Hochhaus A, Goldman JM, ... Shah NP, et al. Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia. Journal of Clinical Oncology. 31: 7001-7001. DOI: 10.1200/Jco.2013.31.15_Suppl.7001 |
0.456 |
|
| 2013 |
Cortes JE, Hochhaus A, Kim D, Shah NP, Mayer J, Rowlings P, Nakamae H, Bradley-Garelik MB, Mohamed H, Kantarjian HM, Saglio G. Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response Blood. 122: 653-653. DOI: 10.1182/Blood.V122.21.653.653 |
0.364 |
|
| 2013 |
Deininger MW, Shah NP, Cortes JE, Kim D, Nicolini FE, Talpaz M, Baccarani M, Muller MC, Li J, Lustgarten S, Clackson T, Turner CD, Haluska FG, Hodgson G, Rivera VM, et al. Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) Blood. 122: 652-652. DOI: 10.1182/Blood.V122.21.652.652 |
0.39 |
|
| 2013 |
Cortes JE, Kim D, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, ... ... Shah NP, et al. Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial Blood. 122: 650-650. DOI: 10.1182/Blood.V122.21.650.650 |
0.406 |
|
| 2013 |
Cortes JE, Kim D, Coutre PDL, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Dipersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, ... ... Shah NP, et al. Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) Blood. 122: 4007-4007. DOI: 10.1182/Blood.V122.21.4007.4007 |
0.341 |
|
| 2013 |
Smith CC, Lin K, Lasater E, Stewart W, Damon LE, Kasarskis A, Bashir A, Pendleton M, Sebra R, Perl AE, Le MH, Zhang C, West B, Shah NP. Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML) Blood. 122: 3938-3938. DOI: 10.1182/Blood.V122.21.3938.3938 |
0.461 |
|
| 2013 |
Smith CC, Salerno S, Shah NP. Mutations At The FLT3 Activation Loop D835 Residue Confer Differential Resistance To Clinically Active FLT3 Inhibitors Blood. 122: 3929-3929. DOI: 10.1182/Blood.V122.21.3929.3929 |
0.433 |
|
| 2013 |
Cortes JE, Saglio G, Coutre PDl, Porkka K, Mustjoki S, Mohamed H, Shah NP. The Association Of Dasatinib-Induced Lymphocytosis With Treatment Outcome In Patients With Chronic Myeloid Leukemia (CML) Blood. 122: 2741-2741. DOI: 10.1182/Blood.V122.21.2741.2741 |
0.402 |
|
| 2013 |
Hochhaus A, Cortes JE, Kim D, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, ... ... Shah NP, et al. Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial Blood. 122: 1498-1498. DOI: 10.1182/Blood.V122.21.1498.1498 |
0.345 |
|
| 2013 |
Le Coutre PD, Kim D, Pinilla-Ibarz J, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, Dipersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, ... ... Shah NP, et al. Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs) Blood. 122: 1496-1496. DOI: 10.1182/Blood.V122.21.1496.1496 |
0.36 |
|
| 2013 |
le Coutre PD, Hughes TP, Mahon F, Kim D, Steegmann JL, Shah NP, Wallis N, Cortes JE. Peripheral Arterial Occlusive Disease (PAOD) In Patients (Pts) Receiving Dasatinib: Experience Across Multiple Clinical Trials Blood. 122: 1489-1489. DOI: 10.1182/Blood.V122.21.1489.1489 |
0.35 |
|
| 2013 |
Gajan J, Lasater E, Tajon C, Craik C, Shah N. Abstract 4308: A model of oncogene addiction: BCR-ABL hijacks signaling through a MEK-dependent process and inhibits growth factor-mediated signal transduction. Cancer Research. 73: 4308-4308. DOI: 10.1158/1538-7445.Am2013-4308 |
0.766 |
|
| 2012 |
Smith CC, Shah NP. Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 685-9. PMID 24451819 DOI: 10.14694/EdBook_AM.2012.32.685 |
0.378 |
|
| 2012 |
Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. The New England Journal of Medicine. 367: 2075-88. PMID 23190221 DOI: 10.1056/Nejmoa1205127 |
0.477 |
|
| 2012 |
Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML, Harvey RC, Chen X, Kasap C, Yan C, Becksfort J, Finney RP, ... ... Shah NP, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 22: 153-66. PMID 22897847 DOI: 10.1016/J.Ccr.2012.06.005 |
0.419 |
|
| 2012 |
Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia Nature. 484: 260-263. PMID 22504184 DOI: 10.1038/Nature11016 |
0.458 |
|
| 2012 |
Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Ipiña JJ, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 119: 1123-9. PMID 22160483 DOI: 10.1182/Blood-2011-08-376087 |
0.444 |
|
| 2012 |
Hochhaus A, Shah NP, Cortes JE, Baccarani M, Bradley-Garelik MB, Dejardin D, Kantarjian H. Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. Journal of Clinical Oncology. 30: 6504-6504. DOI: 10.1200/Jco.2012.30.15_Suppl.6504 |
0.308 |
|
| 2012 |
Smith CC, Brown M, Parker WT, Lin K, Travers K, Wang S, Branford S, Shah N. Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects the Evolution of Polyclonal and Compound BCR-ABL Mutations in Patients Who Relapse On Kinase Inhibitor Therapy Blood. 120: 917-917. DOI: 10.1182/Blood.V120.21.917.917 |
0.401 |
|
| 2012 |
Kantarjian HM, Kim D, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo D, Abruzzese E, Rea D, Baccarani M, ... ... Shah N, et al. Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial Blood. 120: 915-915. DOI: 10.1182/Blood.V120.21.915.915 |
0.39 |
|
| 2012 |
Smith CC, Chin J, Lasater E, Paguirigan AL, Lin K, Stewart W, Salerno S, Damon LE, Levis MJ, Perl AE, Travers K, Kasarskis A, Radich JP, Shah N. Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220 Blood. 120: 674-674. DOI: 10.1182/Blood.V120.21.674.674 |
0.438 |
|
| 2012 |
Obholz KL, DeAngelo DJ, Mauro MJ, Shah N, Smith BD, Bowser A, Peterson ED, Radich JP. Clinical Impact of an Internet-Based Tool to Help Guide Therapeutic Changes While Monitoring Patients with Chronic Myeloid Leukemia Receiving First-Line Tyrosine Kinase Inhibitor Therapy Blood. 120: 4279-4279. DOI: 10.1182/Blood.V120.21.4279.4279 |
0.376 |
|
| 2012 |
Hochhaus A, Kim D, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo D, Abruzzese E, Rea D, Baccarani M, ... ... Shah N, et al. Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial Blood. 120: 3763-3763. DOI: 10.1182/Blood.V120.21.3763.3763 |
0.44 |
|
| 2012 |
Kim D, Cortes JE, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo D, Abruzzese E, Rea D, Baccarani M, ... ... Shah N, et al. Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial Blood. 120: 3749-3749. DOI: 10.1182/Blood.V120.21.3749.3749 |
0.425 |
|
| 2012 |
Mauro MJ, Cortes JE, Kim D, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, ... ... Shah N, et al. Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial Blood. 120: 3747-3747. DOI: 10.1182/Blood.V120.21.3747.3747 |
0.406 |
|
| 2012 |
Deininger MW, Cortes JE, Kantarjian HM, Shah N, Bixby D, Mauro MJ, Flinn IW, O'Hare T, Hu S, Dorer DJ, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, et al. Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study Blood. 120: 3743-3743. DOI: 10.1182/Blood.V120.21.3743.3743 |
0.423 |
|
| 2012 |
Cheng W, Lasater E, Smith CC, Mokang M, Bao Y, Shah N. Competitive Allele Specific TaqMan® PCR (castPCR™) Technology for Sensitive Detection of AC220-Resistant FLT3 Kinase Domain Mutations in Primary AML Patient Samples. Blood. 120: 2559-2559. DOI: 10.1182/Blood.V120.21.2559.2559 |
0.412 |
|
| 2012 |
Saglio G, Kantarjian HM, Shah N, Jabbour EJ, Quintas-Cardama A, Steegmann JL, Boqué C, Chuah C, Pavlovsky C, Mayer J, Ukropec J, Wildgust M, Hochhaus A. Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data Blood. 120: 1675-1675. DOI: 10.1182/Blood.V120.21.1675.1675 |
0.36 |
|
| 2012 |
Cortes JE, Kim D, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, ... ... Shah N, et al. A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial Blood. 120: 163-163. DOI: 10.1182/Blood.V120.21.163.163 |
0.428 |
|
| 2012 |
Smith CC, Lasater E, Mccreery M, Lin K, Stewart W, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Shah N. Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants Blood. 120: 141-141. DOI: 10.1182/Blood.V120.21.141.141 |
0.476 |
|
| 2012 |
Lasater EA, Smith CC, Shah NP. Abstract 1893: Activating NRAS mutations are associated with FLT3-independent resistance to the clinically active FLT3 inhibitor AC220in vitro Cancer Research. 72: 1893-1893. DOI: 10.1158/1538-7445.Am2012-1893 |
0.486 |
|
| 2011 |
Talpaz M, Shah NP, Deininger MW, Mauro MJ, Flinn IW, Lustgarten S, Lindmark W, Gozgit JM, Clackson T, Turner CD, Haluska FG, Kantarjian H, Cortes JE. Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6518. PMID 28019981 DOI: 10.1200/Jco.2011.29.15_Suppl.6518 |
0.341 |
|
| 2011 |
Smith CC, Shah NP. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2011: 121-7. PMID 22160023 DOI: 10.1182/Asheducation-2011.1.121 |
0.461 |
|
| 2011 |
Smith CC, Shah NP. Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia Clinical Cancer Research. 17: 6605-6607. PMID 21948230 DOI: 10.1158/1078-0432.Ccr-11-2240 |
0.34 |
|
| 2011 |
Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, ... Shah NP, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. The Journal of Experimental Medicine. 208: 2163-74. PMID 21911423 DOI: 10.1084/Jem.20110304 |
0.469 |
|
| 2011 |
Paquette RL, Nicoll J, Chalukya M, Elashoff D, Shah NP, Sawyers C, Spiteri E, Nanjangud G, Rao PN. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. Cancer Genetics. 204: 392-7. PMID 21872826 DOI: 10.1016/J.Cancergen.2011.06.002 |
0.491 |
|
| 2011 |
Shah NP, Kantarjian H, Kim D, Hochhaus A, Saglio G, Guilhot F, Schiffer CA, Steegmann JL, Mohamed H, Dejardin D, Healey DI, Cortes JE. Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. Journal of Clinical Oncology. 30: 6506-6506. DOI: 10.1200/Jco.2012.30.15_Suppl.6506 |
0.379 |
|
| 2011 |
Smith CC, Chin J, Wang Q, Salerno S, Damon LE, Hunt JP, Levis MJ, Perl AE, Travers K, Wang S, Kasarskis A, Schadt E, Kuriyan J, Shah N. Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia Blood. 118: 937-937. DOI: 10.1182/Blood.V118.21.937.937 |
0.484 |
|
| 2011 |
Smith CC, Damon LE, Zhu X, Salerno S, Shah N. Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants Blood. 118: 930-930. DOI: 10.1182/Blood.V118.21.930.930 |
0.448 |
|
| 2011 |
Smith CC, Perl AE, Lasater E, Zhang C, Jeschke GR, Damon LE, Carroll M, Shah NP. PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro Blood. 118: 764-764. DOI: 10.1182/Blood.V118.21.764.764 |
0.493 |
|
| 2011 |
Roberts KG, Morin RD, Zhang J, Hirst M, Harvey RC, Kasap C, Chen X, Edmonson M, Chen I, Shah N, Devidas M, Reaman GH, Smith MA, Pui C, Downing JR, et al. Novel Chromosomal Rearrangements and Sequence Mutations in High-Risk Ph-Like Acute Lymphoblastic Leukemia Blood. 118: 67-67. DOI: 10.1182/Blood.V118.21.67.67 |
0.425 |
|
| 2011 |
Cortes JE, Kantarjian HM, Shah N, Bixby D, Mauro MJ, Flinn IW, O'Hare T, Hu S, Clackson T, Rivera VM, Turner CD, Haluska F, Druker BJ, Deininger MW, Talpaz M. Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies Blood. 118: 602-602. DOI: 10.1182/Blood.V118.21.602.602 |
0.433 |
|
| 2011 |
Hurtz C, Hatzi K, Cerchietti L, Park E, Kim Y, Ramezani-Rad P, Jumaa H, Muller MC, Hofmann W, Hochhaus A, Agarwal A, Shah N, Melnick A, Druker BJ, Muschen M. BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia Blood. 118: 446-446. DOI: 10.1182/Blood.V118.21.446.446 |
0.477 |
|
| 2011 |
Smith CC, Brown M, Chin J, Kasap C, Salerno S, Damon LE, Travers K, Wang S, Kasarskis A, Schadt E, Shah N. Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy, Blood. 118: 3752-3752. DOI: 10.1182/Blood.V118.21.3752.3752 |
0.435 |
|
| 2011 |
Hochhaus A, Saglio G, Chuah C, Pavlovsky C, Garelick MBB, Lambert A, Shah N. Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial Blood. 118: 2767-2767. DOI: 10.1182/Blood.V118.21.2767.2767 |
0.388 |
|
| 2011 |
Fiskus W, Smith CC, Smith J, Wise SC, Lasater E, Damon LE, Salerno S, Fleming A, Reyes R, Ganguly S, Berger MS, Rutkoski TJ, McGuirk J, Shah N, Bhalla KN. Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations Blood. 118: 2611-2611. DOI: 10.1182/Blood.V118.21.2611.2611 |
0.487 |
|
| 2011 |
Shah N, Matevosyan K, Burner J, Sarode R. ADAMTS13 Helps Distinguish Thrombotic Thrombocytopenic Purpura From Other Microangiopathies and Guide Necessity of Plasma Exchange Therapy Blood. 118: 2328-2328. DOI: 10.1182/Blood.V118.21.2328.2328 |
0.327 |
|
| 2011 |
Smith CC, Damon L, Salerno S, Shah NP. Abstract 4737: Saturation mutagenesis of FLT3-ITD: AC220-resistance-conferring kinase domain mutations are restricted to a limited number of residues and are cross-resistant to sorafenib in vitro Cancer Research. 71: 4737-4737. DOI: 10.1158/1538-7445.Am2011-4737 |
0.487 |
|
| 2011 |
Gajan J, Oses-prieto J, Lasater EA, Burlingame A, Shah NP. Abstract 2923: Phosphoproteomic assessment of CML cells following transient potent inhibition with dasatinib is associated with durable alteration of the STAT5 and RAF/MEK/ERK pathways Cancer Research. 71: 2923-2923. DOI: 10.1158/1538-7445.Am2011-2923 |
0.765 |
|
| 2010 |
Kantarjian H, Shah NP, Hochhaus A, Cortes JE, Shah S, Ayala M, Moiraghi B, Bradley-Garelik M, Zhu C, Baccarani M. Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: LBA6500. PMID 27937447 DOI: 10.1200/jco.2010.28.18_suppl.lba6500 |
0.301 |
|
| 2010 |
Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. The New England Journal of Medicine. 362: 2260-70. PMID 20525995 DOI: 10.1056/Nejmoa1002315 |
0.422 |
|
| 2010 |
Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 95: 232-40. PMID 20139391 DOI: 10.3324/Haematol.2009.011452 |
0.42 |
|
| 2010 |
Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. American Journal of Hematology. 85: 164-70. PMID 20131302 DOI: 10.1002/Ajh.21615 |
0.359 |
|
| 2010 |
Paquette RL, Nicoll J, Chalukya M, Gondek L, Jasek M, Sawyers CL, Shah NP, Maciejewski J. Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Leukemia Research. 34: 708-13. PMID 19804904 DOI: 10.1016/J.Leukres.2009.08.032 |
0.344 |
|
| 2010 |
Shah NP, Cortes JE, Schiffer CA, Coutre Pl, Bahceci E, Lambert A, Saglio G. Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily. Journal of Clinical Oncology. 28: 6512-6512. DOI: 10.1200/Jco.2010.28.15_Suppl.6512 |
0.35 |
|
| 2010 |
Schiffer CA, Cortes JE, Saglio G, Coutre Pl, Guilhot F, Bahceci E, Dejardin D, Shah NP. Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib Blood. 116: 358-358. DOI: 10.1182/Blood.V116.21.358.358 |
0.402 |
|
| 2010 |
Cortes JE, Shah NP, Schiffer CA, LeCoutre PD, Saglio G, Quintás-Cardama A, Kantarjian H, Jabbour E, Bahceci E, Chen A, Lambert A, Guilhot F. Significance of ELN Provisional Response Definitions In Predicting Long-Term Outcomes of Patients with CP-CML Treated with Dasatinib After Imatinib Failure. Blood. 116: 3439-3439. DOI: 10.1182/Blood.V116.21.3439.3439 |
0.369 |
|
| 2010 |
Khoury HJ, Cortes JE, Kantarjian H, Baccarani M, Shah NP, Bradley-Garelik MB, Dejardin D, Hochhaus A. Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial. Blood. 116: 3421-3421. DOI: 10.1182/Blood.V116.21.3421.3421 |
0.319 |
|
| 2010 |
Quintás-Cardama A, Kantarjian H, Shah NP, Schiffer CA, Coutre Pl, Saglio G, Guilhot F, Hochhaus A, Müller MC, Bahceci E, Lambert A, Cortes JE. Patients with Chronic Myeloid Leukemia In Chronic Phase Carrying More Than One BCR-ABL Kinase Domain Mutation Exhibit Poorer Response Rates and Outcomes to Second-Line Dasatinib Compared to Those with No or Only One BCR-ABL Mutation Blood. 116: 2297-2297. DOI: 10.1182/Blood.V116.21.2297.2297 |
0.41 |
|
| 2010 |
Guilhot F, Kantarjian H, Shah NP, Hochhaus A, Bradley-Garelik MB, Dejardin D, Cortes JE. Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial Blood. 116: 2295-2295. DOI: 10.1182/Blood.V116.21.2295.2295 |
0.363 |
|
| 2010 |
Saglio G, Hochhaus A, Cortes JE, Kantarjian H, Baccarani M, Bradley-Garelik MB, Dejardin D, Shah NP. Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial Blood. 116: 2286-2286. DOI: 10.1182/Blood.V116.21.2286.2286 |
0.354 |
|
| 2010 |
Cortes J, Talpaz M, Bixby D, Deininger M, Shah N, Flinn IW, Mauro M, O'Hare T, Hu S, Kan R, Rivera VM, Clackson T, Haluska F, Kantarjian H. A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings Blood. 116: 210-210. DOI: 10.1182/Blood.V116.21.210.210 |
0.434 |
|
| 2010 |
Shah N, Kantarjian H, Hochhaus A, Cortes JE, Bradley-Garelik MB, Zhu C, Baccarani M. Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up Blood. 116: 206-206. DOI: 10.1182/Blood.V116.21.206.206 |
0.388 |
|
| 2010 |
Gajan J, Kasap C, Shah N. Abstract 1659: The mechanism of action of clinically effective dual Abl/Aurora kinase inhibitors does not involve BCR-ABL inhibition Cancer Research. 70: 1659-1659. DOI: 10.1158/1538-7445.Am10-1659 |
0.778 |
|
| 2009 |
Stone RM, Kim DW, Kantarjian HM, Rousselot P, Hochhaus A, Dorlhiac-Llacer PE, Milone J, Matloub Y, Lambert A, Shah NP. Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): Three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 7007. PMID 27961379 DOI: 10.1200/Jco.2009.27.15_Suppl.7007 |
0.379 |
|
| 2009 |
Shah NP. Fine-tuning targeted therapy of CML. Blood. 114: 4914-5. PMID 19965702 DOI: 10.1182/Blood-2009-10-246371 |
0.452 |
|
| 2009 |
Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 115: 4136-47. PMID 19536906 DOI: 10.1002/Cncr.24504 |
0.382 |
|
| 2009 |
Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 23: 1398-405. PMID 19295545 DOI: 10.1038/Leu.2009.46 |
0.461 |
|
| 2009 |
Seeliger MA, Ranjitkar P, Kasap C, Shan Y, Shaw DE, Shah NP, Kuriyan J, Maly DJ. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations Cancer Research. 69: 2384-2392. PMID 19276351 DOI: 10.1158/0008-5472.Can-08-3953 |
0.399 |
|
| 2009 |
Oehler VG, Qin J, Ramakrishnan R, Facer G, Ananthnarayan S, Cummings C, Deininger M, Shah N, McCormick F, Willis S, Daridon A, Unger M, Radich JP. Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia. 23: 396-399. PMID 18615105 DOI: 10.1038/Leu.2008.183 |
0.408 |
|
| 2009 |
Cortes J, Talpaz M, Deininger M, Shah N, Flinn IW, Mauro MJ, O'Hare T, Spinos N, Hu S, Berk L, Narasimhan N, Rivera VM, Clackson T, Haluska F, Kantarjian HM. A Phase 1 Trial of Oral AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Other Hematologic Malignancies: First Results of Safety and Clinical Activity against T315I and Resistant Mutations. Blood. 114: 643-643. DOI: 10.1182/Blood.V114.22.643.643 |
0.399 |
|
| 2009 |
Shah N, Bahceci E, Lambert A, Ploughman L, Radich J. Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP). Blood. 114: 1122-1122. DOI: 10.1182/Blood.V114.22.1122.1122 |
0.46 |
|
| 2009 |
Shah NP. Fine-tuning targeted therapy of CML Blood. 114: 4914-4915. DOI: 10.1182/blood-2009-10-246371 |
0.322 |
|
| 2008 |
Wang X, Hochhaus A, Kantarjian HM, Agrawal S, Roy A, Pfister M, Chen T, Bleickardt E, Nicaise C, Shah N. Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3590. PMID 27949703 DOI: 10.1200/Jco.2008.26.15_Suppl.3590 |
0.338 |
|
| 2008 |
Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 14: 485-93. PMID 19061839 DOI: 10.1016/J.Ccr.2008.11.001 |
0.461 |
|
| 2008 |
Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3204-12. PMID 18541900 DOI: 10.1200/Jco.2007.14.9260 |
0.4 |
|
| 2008 |
Shah NP. Bench to bedside: BRCA: From therapeutic target to therapeutic shield Nature Medicine. 14: 495-496. PMID 18463659 DOI: 10.1038/Nm0508-495 |
0.347 |
|
| 2008 |
Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 22: 1200-6. PMID 18401416 DOI: 10.1038/Leu.2008.84 |
0.44 |
|
| 2008 |
Shah NP. Advanced CML: Therapeutic options for patients in accelerated and blast phases Jnccn Journal of the National Comprehensive Cancer Network. 6. PMID 18397679 |
0.339 |
|
| 2008 |
Shah NP, Olszynski P, Sokol L, Verstovsek S, Hoffman R, List AF, Cortes J, Kantarjian HM, Gilliland DG, Clary DO, Bui LA, Wadleigh M. A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Blood. 112: 98-98. DOI: 10.1182/Blood.V112.11.98.98 |
0.419 |
|
| 2008 |
Kasap C, Hertz N, Makino D, Shokat K, Kuriyan J, Shah NP. Beyond the Gatekeeper: Imatinib- and Dasatinib-Resistant BCR-ABL/F317 Mutations Confer Cross-Resistance to VX-680 but Are Sensitive to a Structural Derivative of VX-680 Blood. 112: 725-725. DOI: 10.1182/Blood.V112.11.725.725 |
0.501 |
|
| 2008 |
Paquette R, Nicoll J, Chalukya M, Gondek LP, Jasek M, Sawyers C, Shah N, Maciejewski J. Clonal Hematopoiesis in Philadelphia Chromosome-Negative Bone Marrow Cells of Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors Blood. 112: 575-575. DOI: 10.1182/Blood.V112.11.575.575 |
0.399 |
|
| 2008 |
Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Burnette PE, Garzon F, Gedde-Dahl T, Hernesniemi S, Hjorth-Hansen H, Hoglund M, Juvonen V, Kairisto V, Kovanen P, Kreutzman A, Laurinolli T, ... ... Shah N, et al. Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy Blood. 112: 573-573. DOI: 10.1182/Blood.V112.11.573.573 |
0.429 |
|
| 2008 |
Cortes J, Paquette R, Talpaz M, Pinilla J, Asatiani E, Wetzler M, Lipton JH, Kasap C, Bui LA, Clary DO, Shah N. Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation Blood. 112: 3232-3232. DOI: 10.1182/Blood.V112.11.3232.3232 |
0.409 |
|
| 2008 |
Shah NP, Kim D, Kantarjian HM, Rousselot P, Dorlhiac-Llacer P, Milone J, Müller MC, Matloub Y, Lambert A, Hochhaus A. Dasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-Year Data from CA180-034 Show Equivalent Long-Term Efficacy and Improved Safety with 100 Mg Once Daily Dose Blood. 112: 3225-3225. DOI: 10.1182/Blood.V112.11.3225.3225 |
0.345 |
|
| 2008 |
Larson RA, Ottmann OG, Shah NP, Lilly MB, Reiffers JM, Charbonnier A, Ehninger G, Bradley-Garelik MB, Zhu C, Martinelli G. Dasatinib 140 Mg Once Daily (QD) Has Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Imatinib-Resistant or -Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 2-Year Data from CA180- 035 Blood. 112: 2926-2926. DOI: 10.1182/Blood.V112.11.2926.2926 |
0.392 |
|
| 2008 |
Paquette R, Sokol L, Shah NP, Silver RT, List AF, Clary DO, Bui LA, Talpaz M. A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera Blood. 112: 2810-2810. DOI: 10.1182/Blood.V112.11.2810.2810 |
0.411 |
|
| 2007 |
Shah NP. Medical management of CML Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 371-375. PMID 18024653 DOI: 10.1182/Asheducation-2007.1.371 |
0.438 |
|
| 2007 |
Shah NP. Progressive thoughts about progressive disease Clinical Cancer Research. 13: 5229-5231. PMID 17875748 DOI: 10.1158/1078-0432.Ccr-07-0678 |
0.386 |
|
| 2007 |
Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency Journal of Clinical Investigation. 117: 2562-2569. PMID 17710227 DOI: 10.1172/Jci30890 |
0.497 |
|
| 2007 |
Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes T, ... ... Shah N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 109: 5143-50. PMID 17317857 DOI: 10.1182/Blood-2006-11-056028 |
0.409 |
|
| 2007 |
Shah NP. Dasatinib. Drugs of Today (Barcelona, Spain : 1998). 43: 5-12. PMID 17315048 DOI: 10.1358/dot.2007.43.1.1050791 |
0.35 |
|
| 2007 |
Shankar DB, Li J, Tapang P, Owen McCall J, Pease LJ, Dai Y, Wei RQ, Albert DH, Bouska JJ, Osterling DJ, Guo J, Marcotte PA, Johnson EF, Soni N, Hartandi K, ... ... Shah N, et al. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood. 109: 3400-8. PMID 17209055 DOI: 10.1182/Blood-2006-06-029579 |
0.449 |
|
| 2007 |
Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 109: 3207-13. PMID 17185463 DOI: 10.1182/Blood-2006-09-046888 |
0.476 |
|
| 2007 |
Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, ... ... Shah NP, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 109: 2303-9. PMID 17138817 DOI: 10.1182/Blood-2006-09-047266 |
0.478 |
|
| 2007 |
Hochhaus A, Branford S, Radich J, Mueller MC, Shah N, Erben P, Ernst T, Acevedo M, Nicaise C, Hughes T. Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR- ABL mutations Journal of Clinical Oncology. 25: 7023-7023. DOI: 10.1200/Jco.2007.25.18_Suppl.7023 |
0.451 |
|
| 2007 |
Shah NP, Kim DW, Kantarjian HM, Rousselot P, Dorlhiac-Llacer PE, Milone JH, Bleickardt E, Francis S, Hochhaus A. Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: One-year results of CA180034 Journal of Clinical Oncology. 25: 7004-7004. DOI: 10.1200/Jco.2007.25.18_Suppl.7004 |
0.374 |
|
| 2007 |
Kantarjian HM, Rousselot P, Pasquini R, Hamerschlak N, Holowiecki J, Dejardin D, Bleickardt E, Shah NP. Dasatinib or High-Dose Imatinib for Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant to Standard-Dose Imatinib: 2-Year Follow-Up Data from START-R (CA180-017). Blood. 110: 736-736. DOI: 10.1182/Blood.V110.11.736.736 |
0.412 |
|
| 2007 |
Verstovsek S, Pardanani AD, Shah NP, Sokol L, Wadleigh M, Gilliland DG, List AF, Tefferi A, Kantarjian HM, Bui LA, Clary DO. A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Blood. 110: 553-553. DOI: 10.1182/Blood.V110.11.553.553 |
0.415 |
|
| 2007 |
Shah NP, Kasap C, Paquette R, Cortes J, Pinilla J, Talpaz M, Bui LA, Clary DO. Targeting Drug-Resistant CML and Ph+-ALL with the Spectrum Selective Protein Kinase Inhibitor XL228. Blood. 110: 474-474. DOI: 10.1182/Blood.V110.11.474.474 |
0.5 |
|
| 2007 |
Kasap C, Weier C, Shah NP. Optimal Treatment for Patients after Dasatinib or Nilotinib: Comparison of Preclinical Activities of Approved and Promising Investigational Kinase Inhibitors Against BCR-ABL Kinase Domain Mutations That Confer Clinical Resistance to Dasatinib or Nilotinib. Blood. 110: 4589-4589. DOI: 10.1182/Blood.V110.11.4589.4589 |
0.502 |
|
| 2007 |
Mustjoki S, Laurinolli T, Ekblom M, Rauhala A, Sinisalo M, Almqvist A, Koivunen E, Lundan T, Ebeling F, Koskenvesa P, Hjorth-Hansen H, Arstila P, Stenke L, Steegmann JL, Hoglund M, ... ... Shah N, et al. Clonal Large Granular Lymphocyte (LGL) Expansion Associated with Dasatinib Therapy. Blood. 110: 2938-2938. DOI: 10.1182/Blood.V110.11.2938.2938 |
0.407 |
|
| 2007 |
Paquette RL, Shah NP, Sawyers CL, Martinelli G, John N, Chalukya M, Rocchetti M, Fiocchi C, Comis S, Capolongo L, Laffranchi B. PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL. Blood. 110: 1030-1030. DOI: 10.1182/Blood.V110.11.1030.1030 |
0.493 |
|
| 2007 |
Cortes J, Sawyers CL, Kantarjian HM, Shah NP, Paquette R, Paliwal P, Bleickardt E, Talpaz M. Long-Term Efficacy of Dasatinib in Chronic-Phase CML: Results from the Phase I Trial (CA180002). Blood. 110: 1026-1026. DOI: 10.1182/Blood.V110.11.1026.1026 |
0.493 |
|
| 2006 |
Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. The New England Journal of Medicine. 354: 2531-41. PMID 16775234 DOI: 10.1056/Nejmoa055229 |
0.45 |
|
| 2006 |
Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 103: 2794-9. PMID 16477019 DOI: 10.1073/Pnas.0510423103 |
0.353 |
|
| 2006 |
Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 108: 286-91. PMID 16434489 DOI: 10.1182/Blood-2005-10-3969 |
0.475 |
|
| 2006 |
Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Research. 66: 1007-14. PMID 16424036 DOI: 10.1158/0008-5472.Can-05-2788 |
0.438 |
|
| 2006 |
Shah NP, Rousselot P, Pasquini R, Hamerschlak N, Holowiecki J, Gerard B, Dejardin D, Kantarjian H. Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial Journal of Clinical Oncology. 24: 6507-6507. DOI: 10.1200/Jco.2006.24.18_Suppl.6507 |
0.366 |
|
| 2006 |
Shah NP, Skaggs B, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. Sequential Kinase Inhibitor Therapy in CML Patients Can Select for Cells Harboring Compound BCR-ABL Kinase Domain Mutations with Increased Oncogenic Potency: Rationale for Early Combination Therapy of ABL Kinase Inhibitors. Blood. 108: 751-751. DOI: 10.1182/Blood.V108.11.751.751 |
0.473 |
|
| 2006 |
Shah NP, Skaggs B, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. The Most Common Dasatinib-Resistant BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia Are Sensitive to VX-680: Rationale for Early Combination Kinase Inhibitor Therapy. Blood. 108: 2175-2175. DOI: 10.1182/Blood.V108.11.2175.2175 |
0.498 |
|
| 2006 |
Shah NP, Nicoll JM, Bleickardt E, Nicaise C, Paquette RL, Sawyers CL. Potent Transient Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development. Blood. 108: 2166-2166. DOI: 10.1182/Blood.V108.11.2166.2166 |
0.511 |
|
| 2006 |
Shah N, Pasquini R, Rousselot P, Jootar S, Holowiecki J, Countouriotis A, Dejardin D, Hughes T, Druker BJ. Dasatinib (SPRYCEL®) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study. Blood. 108: 167-167. DOI: 10.1182/Blood.V108.11.167.167 |
0.395 |
|
| 2006 |
Shah NP. Improving upon the promise of targeted therapy of human malignancy: Chronic myeloid leukemia as a paradigm Cancer Chemotherapy and Pharmacology. 58. DOI: 10.1007/S00280-006-0316-4 |
0.513 |
|
| 2005 |
Shah N, Sawyers CL, Kantarjian HM, Donato N, Nicoll J, Cortes J, Paquette R, Huang F, Clark E, Talpaz M. Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6521. PMID 27943866 DOI: 10.1200/Jco.2005.23.16_Suppl.6521 |
0.491 |
|
| 2005 |
Sawyers CL, Shah NP, Kantarjian HM, Cortes J, Paquette R, Nicoll J, Bai SA, Clark E, Decillis AP, Talpaz M. A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant accelerated and blast phase chronic myeloid leukemia (CML): Results from CA180002. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6520. PMID 27943865 DOI: 10.1200/Jco.2005.23.16_Suppl.6520 |
0.431 |
|
| 2005 |
Talpaz M, Kantarjian HM, Paquette R, Shah N, Cortes J, Nicoll J, Bai SA, Huang F, Decillis AP, Sawyers CL. A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): Results from CA180002. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6519. PMID 27943847 DOI: 10.1200/Jco.2005.23.16_Suppl.6519 |
0.463 |
|
| 2005 |
Shah NP. Loss of response to imatinib: mechanisms and management Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 183-187. PMID 16304378 DOI: 10.1182/Asheducation-2005.1.183 |
0.501 |
|
| 2005 |
Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proceedings of the National Academy of Sciences of the United States of America. 102: 11011-6. PMID 16046538 DOI: 10.1073/Pnas.0504952102 |
0.459 |
|
| 2005 |
Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature. 435: 1267-70. PMID 15988530 DOI: 10.1038/Nature03669 |
0.455 |
|
| 2005 |
Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proceedings of the National Academy of Sciences of the United States of America. 102: 3395-400. PMID 15705718 DOI: 10.1073/Pnas.0409770102 |
0.45 |
|
| 2005 |
Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood. 105: 2093-8. PMID 15345592 DOI: 10.1182/Blood-2004-03-1114 |
0.476 |
|
| 2005 |
Menzel LP, Shankar DB, Shah NP, Hummerickhouse R, Hagey A, Sakamoto KM, Moore TB. 156 ANALYSIS OF A TARGETED RECEPTOR TYROSINE KINASE INHIBITOR IN THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA Journal of Investigative Medicine. 53: S105.1-S105. DOI: 10.2310/6650.2005.00005.155 |
0.389 |
|
| 2005 |
Branford S, Hughes T, Nicoll J, Paquette R, Bleickardt E, Sawyers C, Shah N. Major Molecular Responses to Dasatinib (BMS-354825) Are Observed in Imatinib-Resistant Late Stage Chronic and Advanced CML Patients: Impact and Fate of Imatinib-Resistant Clones in Dasatinib-Treated Patients. Blood. 106: 437-437. DOI: 10.1182/Blood.V106.11.437.437 |
0.455 |
|
| 2005 |
Oehler V, Branford S, Pogosova-Agadjanyan E, Shah N, Sawyers C, Mao M, Linsley P, Hughes T, Radich J. Gene Expression Signatures Associated with Treatment and Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients. Blood. 106: 433-433. DOI: 10.1182/Blood.V106.11.433.433 |
0.416 |
|
| 2005 |
Sawyers CL, Kantarjian H, Shah N, Cortes J, Paquette R, Donato N, Nicoll J, Bleickardt E, Chen T, Talpaz M. Dasatinib (BMS-354825) in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: Update of a Phase I Study. Blood. 106: 38-38. DOI: 10.1182/Blood.V106.11.38.38 |
0.469 |
|
| 2005 |
Shah NP, Nicoll JM, Branford S, Hughes TP, Paquette RL, Talpaz M, Nicaise C, Huang F, Sawyers CL. Molecular Analysis of Dasatinib Resistance Mechanisms in CML Patients Identifies Novel BCR-ABL Mutations Predicted To Retain Sensitivity to Imatinib: Rationale for Combination Tyrosine Kinase Inhibitor Therapy. Blood. 106: 1093-1093. DOI: 10.1182/Blood.V106.11.1093.1093 |
0.487 |
|
| 2005 |
SHAH N, NICOLL J, SAWYERS C. Targeted therapy for the treatment of imatinib-resistant chronic myeloid leukemia: A pharmacogenetic analysis Clinical Pharmacology & Therapeutics. 77: P17-P17. DOI: 10.1016/J.Clpt.2004.11.066 |
0.52 |
|
| 2004 |
Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (New York, N.Y.). 305: 399-401. PMID 15256671 DOI: 10.1126/Science.1099480 |
0.481 |
|
| 2004 |
Shah NP, Lee FY, Sawyers CL, Akin C. BMS-354825 Is a SRC/ABL Inhibitor with High Nanomolar Activity Against the Kit D816v Mutation, Which Drives Systemic Mastocytosis and Is Imatinib-Resistant. Blood. 104: 797-797. DOI: 10.1182/Blood.V104.11.797.797 |
0.46 |
|
| 2004 |
Burgess MR, Shah NP, Skaggs BJ, Lee FY, Sawyers CL. Comparative Analysis of Two BCR-ABL Small Molecule Inhibitors Reveals Overlapping but Distinct Mechanisms of Resistance. Blood. 104: 552-552. DOI: 10.1182/Blood.V104.11.552.552 |
0.432 |
|
| 2004 |
Shah NP, Branford S, Hughes TP, Nicoll JM, Decillis AP, Sawyers CL. Major Cytogenetic Responses to BMS-354825 in Patients with Chronic Myeloid Leukemia Are Associated with a One to Two Log Reduction in BCR-ABL Transcript. Blood. 104: 1008-1008. DOI: 10.1182/Blood.V104.11.1008.1008 |
0.433 |
|
| 2004 |
Sawyers CL, Shah NP, Kantarjian HM, Donato N, Nicoll J, Bai SA, Huang F, Clark E, DeCillis AP, Talpaz M. Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study. Blood. 104: 1-1. DOI: 10.1182/Blood.V104.11.1.1 |
0.52 |
|
| 2003 |
Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias Oncogene. 22: 7389-7395. PMID 14576846 DOI: 10.1038/Sj.Onc.1206942 |
0.468 |
|
| 2002 |
Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2: 117-25. PMID 12204532 DOI: 10.1016/S1535-6108(02)00096-X |
0.485 |
|
| 2002 |
Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proceedings of the National Academy of Sciences of the United States of America. 99: 10700-5. PMID 12149456 DOI: 10.1073/Pnas.162140299 |
0.488 |
|
| Show low-probability matches. |